Suppr超能文献

A群链球菌C5a肽酶不同片段和结构域的免疫原性评估及其作为糖缀合物疫苗开发载体蛋白的应用潜力

Immunogenicity Assessment of Different Segments and Domains of Group a Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development.

作者信息

Wang Guirong, Zhao Jielin, Zhao Yisheng, Wang Subo, Feng Shaojie, Gu Guofeng

机构信息

National Glycoengineering Research Center and Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, 72 Binhai Road, Qingdao 266237, China.

出版信息

Vaccines (Basel). 2021 Feb 9;9(2):139. doi: 10.3390/vaccines9020139.

Abstract

Group A streptococcal C5a peptidase (ScpA) is a highly conserved surface virulence factor present on group A streptococcus (GAS) cell surfaces. It has attracted much more attention as a promising antigenic target for GAS vaccine development due to its high antigenicity to stimulate specific and immunoprotective antibodies. In this study, a series of segments of ScpA were rationally designed according to the functional domains described in its crystal structure, efficiently prepared and immunologically evaluated so as to assess their potential as antigens for the development of subunit vaccines. Immunological studies revealed that Fn, Fn2, and rsScpA193 proteins were promising antigen candidates worthy for further exploration. In addition, the potential of Fn and Fn2 as carrier proteins to formulate effective glycoconjugate vaccine was also investigated.

摘要

A组链球菌C5a肽酶(ScpA)是A组链球菌(GAS)细胞表面存在的一种高度保守的表面毒力因子。由于其具有高抗原性,能够刺激产生特异性和免疫保护性抗体,作为GAS疫苗开发中一个有前景的抗原靶点,它受到了更多关注。在本研究中,根据ScpA晶体结构中描述的功能域,合理设计了一系列ScpA片段,高效制备并进行了免疫学评估,以评估它们作为亚单位疫苗开发抗原的潜力。免疫学研究表明,Fn、Fn2和rsScpA193蛋白是值得进一步探索的有前景的抗原候选物。此外,还研究了Fn和Fn2作为载体蛋白来制备有效糖缀合物疫苗的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94f3/7915350/a892efcd7201/vaccines-09-00139-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验